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Abstract. Esophageal carcinoma is one of the most aggressive 
malignancies, and is characterized by poor response to current 
therapy and a dismal survival rate. In this study we investigated 
whether irradiation induces epithelial-mesenchymal transition 
(EMT) in esophageal squamous cell carcinoma (ESCC) TE9 
cells and whether the classic histone deacetylase (HDAC) 
inhibitor valproic acid (VPA) suppresses these changes. First, 
we showed that 2 Gy irradiation induced spindle cell-like 
morphologic changes, decreased expression of membranous 
E-cadherin, upregulated vimentin expression, and altered the 
localization of β-catenin from its usual membrane-bound loca-
tion to cytoplasm in TE9 cells. Irradiation induced upregulation 
of transcription factors including Slug, Snail, and Twist, which 
regulate EMT. Stimulation by irradiation resulted in increased 
TGF-β1 and HIF-1α expression and induced Smad2 and 
Smad3 phosphorylation. Furthermore, irradiation enhanced 
CD44 expression, indicating acquisition of cancer stem-like 
cell properties. In addition, irradiation enhanced invasion and 
migration ability with upregulation of matrix metallopro-
teinases. These findings indicate that single-dose irradiation 
can induce EMT in ESCC cells. Second, we found that treat-
ment with 1 mM VPA induced reversal of EMT caused by 
irradiation in TE9 cells, resulting in attenuated cell invasion 
and migration abilities. These results suggest that VPA might 
have clinical value to suppress irradiation-induced EMT. The 
reversal of EMT by HDAC inhibitors may be a new therapeutic 
strategy to improve the effectiveness of radiotherapy in ESCC 
by inhibiting the enhancement of invasion and metastasis.
Introduction
Esophageal carcinoma is one of the most common malignan-
cies of the digestive system. In 2011, esophageal carcinoma 
was the fifth and eighth most common cause of death world-
wide in men and women, respectively (1). Among this group 
of cancers, esophageal squamous cell carcinoma (ESCC) has 
high metastatic potential with frequent initial dissemination to 
regional lymph nodes and distant metastases at diagnosis, char-
acteristics that underlie the majority of ESCC-related deaths 
(2,3). Despite recent advances in clinical treatment, patients 
with ESCC exhibit a poor prognosis, with an average 5-year 
survival rate of <20% worldwide due to distant metastases 
(4). Although the standard treatment for most solid cancers is 
surgical resection, most patients with unresectable malignant 
tumors, including ESCC, are treated by irradiation-based 
therapy. In recent years, ~50% of all patients with solid cancer 
received radiation therapy. However, several recent preclinical 
and clinical studies have demonstrated that irradiation induces 
an increase in invasiveness and metastatic potential of several 
cancer cell types, including glioma, colon, breast, and lung 
cancer (5-7). Elucidation of the mechanisms underlying irra-
diation-induced metastasis is important to overcome failure of 
radiation therapy.
Epithelial mesenchymal transition (EMT) has become 
recognized as one of the major factors causing metastatic 
relapse and resistance to anticancer agents (8,9). EMT is a 
crucial process in cancer progression, providing cancer cells 
with the ability to escape from the primary site, invade stromal 
tissues, and migrate to distant regions of the body. As a result of 
EMT epithelial cells lose their defined cell-cell/cell-substratum 
contacts and their structural/functional polarity and become 
spindle shaped and morphologically similar to activated fibro-
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blasts. At the molecular level, epithelial cells undergoing EMT 
are characterized by downregulation of epithelial makers 
(such as E-cadherin and β-catenin) and loss of cell polarity 
and intercellular adhesion molecules, concomitant with upreg-
ulation of mesenchymal markers (vimentin, N-cadherin, and 
fibronectin) and nuclear localization of β-catenin (10,11). Cells 
that gain expression of mesenchymal markers show a front-
rear polarity associated with weak cell-cell contact, increased 
motility, and resistance to apoptosis (10). Tumor cells that 
gain a more mesenchymal-like phenotype have migratory 
capacity at the expense of proliferative potential, and acquire 
resistance to DNA damage inducers including chemical agents 
and irradiation, thus becoming resistant to chemotherapy and 
radiotherapy (8,9). Transforming growth factor-β1 (TGF-β1) 
is a multifunctional cytokine that modulates cell proliferation, 
differentiation, apoptosis, and extracellular matrix production 
(12). TGF-β1 is known to play a critical role in EMT (13). 
TGF-β1 mediates its effects through binding to a heteromeric 
complex of transmembrane serine/threonine kinases and a 
type II receptor, which results in activation of the receptor 
and initiation of Smad-dependent and -independent EMT 
pathways (13,14). Environmental factors, including nicotine, 
ultraviolet light, and irradiation, also promote EMT (15,16). 
Irradiation can cause many cellular effects, including apop-
tosis, senescence, and genomic instability, that may lead 
to cancer cell death. Conversely, irradiation also foments 
an increase in extra- and intracellular levels of TGF-β1 in 
patients and induces acceleration of metastatic cancer progres-
sion (6,17,18). Recently, irradiation was found to enhance cell 
migration, invasion, and metastasis through induction of EMT 
in various cancer cell lines, including ESCC cells (7,19).
Histone deacetylases (HDACs) are a family of enzymes 
that remove acetyl groups from histone and non-histone 
proteins and play an important role in regulating gene 
transcription and protein functions (20). HDAC inhibitors 
induce cell cycle arrest, differentiation, and apoptosis in 
vitro and in vivo (21-23). Over the last year several HDAC 
inhibitors have been introduced into clinical trials with 
successful results. Most epigenetic studies in the anticancer 
field have used valproic acid (VPA), the most potent HDAC 
inhibitor (24). The fact that VPA has been safely used in 
long-term therapy of patients with epilepsy over decades is a 
clear advantage, and phase I and II clinical trials of VPA in 
cancer have provided promising results (25,26). In addition, 
tests of several protocols involving the use of VPA against 
diverse neoplasias are ongoing (20). VPA is a promising 
anticancer agent with effects correlated with the transcrip-
tional regulation of specific cancer-related genes. We have 
noted the effectiveness of VPA as an anticancer agent and 
its ability to suppress collagen synthesis. In previous studies, 
we demonstrated that VPA enhances irradiation-induced 
cytotoxicity via chromatin decondensation and inhibition of 
DNA double-strand break (DSB) repair in human ESCC cells 
(27,28). VPA also prevents the morphologic changes charac-
teristic of activation and inhibits the expression of collagen 
type1 α1 and TGF-β1 in human hepatic stellate cells (29). 
Recently, several reports have shown that HDAC inhibitors 
suppress metastatic potential in cancer cells by attenuating 
EMT (30,31). However, there are no data on the potential role 
of VPA in the inhibition of irradiation-induced EMT.
The aim of this study was to evaluate the inhibitory effects 
of VPA on radiation-induced EMT in human ESCC cells and 
to reveal the underlying mechanisms.
Materials and methods
Cell lines, cell culture, and treatment. The TE9 cell line 
(human ESCC cell line, poorly differentiated) was kindly 
provided by Dr Tetsuro Nishihira (Kenotokorozawa Hospital, 
Saitama, Japan). Cells were grown in RPMI-1640 (Invitrogen, 
Tokyo, Japan) medium supplemented with 2 mM glutamine, 
10% fetal bovine serum (FBS; Nichirei Biosciences, Inc., 
Tokyo, Japan), 100 U/l penicillin, and 100 µg/ml streptomycin 
(Invitrogen) and maintained at 37˚C in a 5% CO2 incubator. The 
cells were seeded in gelatin-coated 75-cm2 flasks (BioCoat, 
BD Biosciences, NJ, USA) and harvested with 0.25% trypsin-
EDTA before use.
Irradiation. Cultures were irradiated using MBR-150R-3 
(Hitachi Medicotechnology, Hitachi, Japan) at a dose rate of 
1.5 Gy/min. Power output of X-ray irradiation was 125 kV, 
20 mA. Forward-scattered radiation, 0.5-mm Al, and 0.2-mm 
Cu filters were used.
Reagents and antibodies. VPA was purchased from Sigma-
Aldrich Co. (Tokyo, Japan) and used at concentrations of 
0.1, 0.5, 1, 5 and 10 mM. VPA was dissolved in phosphate-
buffered saline (PBS) to a stock concentration of 100 mM and 
stored at -20˚C. TGF-β1 was purchased from Sigma-Aldrich 
and used at a concentration of 10 ng/ml. Mouse monoclonal 
antibodies to E-cadherin, vimentin, TGF-β1, Smad2, Smad3, 
matrix metalloproteinase 9 (MMP-9), HCAM (CD44), and 
β-catenin and rabbit polyclonal antibodies to phosphorylated 
Smad2 (p-Smad2), phosphorylated Smad3 (p-Smad3), Twist, 
Snail, Slug, and MMP-7 were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal 
antibodies to MMP-2 were obtained from Millipore (Billerica, 
MA, USA). Mouse monoclonal antibodies to β-actin and 
HIF-1α were obtained from Sigma-Aldrich and Thermo Fisher 
Scientific (Rockford, IL, USA), respectively.
Cell viability assay. TE9 cells were plated in small dishes at 
a density of 5x104/ml in medium with 10% FBS and allowed 
to adhere for 24 h before incubation in serum-free medium for 
24 h. Cells were treated with vehicle or VPA (0, 0.1, 0.5, 1, 5, 
10 mM) for 48 h and harvested by trypsinization. Cells were 
stained with a 0.4% trypan blue solution (Sigma Chemical 
Co., St. Louis, MO, USA), and counted on a Cellometer Vision 
automated cell counter (Nexcelom Bioscience, Lawrence, 
MA, USA) according to the manufacturer's protocol. Cell 
viabilities were represented as mean percentage relative to 
matched vehicle-treated cells for triplicate experiments with 
internal triplicates. At least three independent experiments 
were performed for statistical analysis.
Cell growth assay. The total number of living cells as a measure 
of proliferation was determined using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) 
assay. Cells were seeded in quadruplicate in 95-well plates 
(BD BioCoat) with 5x103 cells per well and incubated for 24 h 
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at 37˚C. After incubation, the supernatant was discarded and 
replaced with fresh serum-free medium. VPA was dissolved in 
PBS and added to the cell culture medium at various concen-
trations (0, 0.1, 0.5, 1, 5 and 10 mM). After 48-h exposure 
to VPA, the cells were incubated at 37˚C for 3 h with MTT 
solution (500 µg/ml) in fresh culture medium. The medium 
was removed and crystallized formazan dye in the cells was 
solubilized by addition of dimethylsulfoxide. The percentage 
inhibition was determined by comparing absorbance at 540 nM 
of VPA-treated cells with that of untreated controls using a 
microplate reader (Bio-Rad 550; Bio-Rad, Japan). Three inde-
pendent experiments were performed for statistical analysis.
Fluorescence immunocytochemistry. TE9 cells were grown 
on a 2-well Lab-Tek Chamber Slide System (Nalge Nunc 
International, Rochester, NY, USA) to 80% confluence 
and incubated for 24-48 h at 37˚C in a humid atmosphere 
of 5% CO2/95% air. Subconfluent cells were transferred 
to serum-free medium for 24 h, and then treated with 2 Gy 
irradiation or 10 ng/ml TGF-β1 with or without 3-h pretreat-
ment with 1 mM VPA. At 24- to 48 h after exposure to 
irradiation or TGF-β1, morphologic changes were observed by 
phase-contrast microscopy. The cells were then subjected to 
immunostaining. Cells on coverslips were fixed with methanol 
and acetone (1:1 v/v). After pretreatment with protein blocking 
serum for 10 min at room temperature to block non-specific 
binding, TE9 cells were incubated with primary antibody 
[anti-E-cadherin (1:200), anti-vimentin (1:200), or anti-β-
catenin (1:100)] overnight at 4˚C. Following washes in PBS, 
cells were incubated with the appropriate Alexa Fluor® 488 
and 592 nm (Molecular Probes/Invitrogen, OR, USA; 1:400) 
for 1 h at room temperature. Nuclei were counterstained with 
bis-benzimide (Hoechst 33258; Sigma-Aldrich Co.) for 5 min 
and cells were visualized with an immunofluorescence micro-
scope (BX50/BX-FLA; Olympus, Japan).
Invasion assay. Cell invasion ability was analyzed by an 
invasion assay using a BioCoat Matrigel Invasion Chamber 
for 24-well plates (BD Bioscience). In brief, Matrigels were 
rehydrated before use. Cells were treated with TGF-β1 or irra-
diation as described above and seeded into the upper chamber 
system in serum-free media (5x104 cells/well) with the control 
or Matrigel membrane. The lower chamber contained 750 µl 
of fresh medium with 10% FBS. After 24-h incubation at 37˚C 
in a humid atmosphere of 5% CO2/95% air, the upper surface 
of the filter was wiped with a cotton swab and fixed in 100% 
methanol. Cells on the lower surface of the membrane were 
stained by hematoxylin and counted using a microscope. The 
number of cells in three random optical fields (x40 magnifi-
cation) was averaged. Percentage invasion was calculated as 
the ratio of the number of invaded cells through the Matrigel 
membrane relative to that through the control membrane.
Migration assay. Cells were seeded in 6-well culture plates 
and grown to ~80% confluence. The confluent cell mono-
layer was scraped with a 10-µl pipette tip. Cells were treated 
with TGF-β1 or irradiation as described above. Images were 
captured immediately after wounding (0 h) and after 48-h 
incubation at 37˚C in a humid atmosphere of 5% CO2/95% air. 
Percentage of migration was calculated as the ratio of migrated 
cells from the leading edge 48 h after scratching relative to 
that in control experiments.
Western blotting. Expression of EMT-related proteins was 
analyzed by western blotting. First, cells were lysed in RIPA 
buffer (Wako Pure Chemical Industries, Ltd., Osaka, Japan) 
containing a protease and phosphatase inhibitor cocktail 
(Sigma-Aldrich). The protein concentration of each sample was 
measured using a BCA protein assay kit (Thermo Scientific, 
Waltham, MA, USA). For sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), 20 µg of protein from 
each sample was separated on a 12.5% gradient polyacrylamide 
gel (e-PAGEL, ATTO Corp., Tokyo, Japan) and transferred to 
polyvinylidene difluoride membranes (Bio-Rad Laboratories). 
After incubation with blocking solution (EZ Block ATTO 
Corp.) at room temperature for 30 min, the membranes 
were incubated with primary antibody overnight at 4˚C, 
followed by incubation with horseradish peroxidase-labeled 
anti-mouse or anti-rabbit IgG secondary antibody (Santa 
Cruz Biotechnology) for 1 h at room temperature. Immune 
complexes were detected using the ECL Plus Western blotting 
detection system (GE Healthcare UK, Ltd., Buckinghamshire, 
UK) and the Light Capture system (ATTO Co. Ltd.). The 
density of each band was quantified by the CS analyzer 
program (Atto Co. Ltd.). We used primary antibodies against 
the following proteins: E-cadherin (1:500), vimentin (1:500), 
β-catenin (1:1,000), TGF-β1 (1:1,000), Smad2 (1:200), Smad3 
(1:200), phosphorylated-Smad2 (p-Smad2) (1:200), p-Smad3 
(1:200), Twist (1:200), Snail (1:200), Slug (1:200), pro-MMP-2 
(1:200), pro-MMP-7 (1:200), pro-MMP-9 (1:200), and HIF-1α 
(1:500). Antibody against β-actin (1:10,000) was used as an 
internal control.
Flow cytometry. To detect CD44, f low cytometry was 
performed using standard protocols. Cells were harvested 
with 0.25% trypsin-EDTA. Cell suspension and anti-CD44 
antibody (1:20) were mixed and incubated for 15 min at room 
temperature. After centrifugation at 2,000 rpm for 3 min at 
4˚C to remove debris, cells were analyzed on a BD FACS 
Calibur flow cytometer (Beckman Coulter, Brea, CA, USA).
Data analysis. All experiments were independently performed 
at least three times and the results were expressed as mean 
± SD. Data were analyzed with SPSS statistics 19 (SPSS Inc., 
Chicago, IL, USA) by Student's unpaired t-test and χ2 test. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
In vitro effect of VPA on cytostasis and cytotoxicity of TE9 
cells. Treatment of TE9 cells with increasing doses (0, 0.5, 1, 
5 and 10 mM) of VPA for 48 h induced a significant dose-
dependent decrease in cell proliferation as assayed by MTT 
metabolism (Fig. 1A). Treatement with 5 and 10 mM VPA 
significantly inhibited TE9 cell proliferation to 55.2±5.3% 
(P=0.0045) and 52.5±5.0% (P=0.004) compared with control, 
respectively. Trypan blue assays revealed no cytotoxic effect 
of VPA against TE9 cells even at the highest concentration 
(10 mM) (Fig. 1B).
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The effect of VPA on morphologic changes induced by 
TGF-β1 or irradiation in TE9 cells. Untreated TE9 cells 
showed a cobblestone-like morphology and strong cell-cell 
adhesion (Fig. 2A). Treatment with 10 ng/ml TGF-β1 or 2 Gy 
of irradiation induced remarkable morphologic changes after 
48 h of stimulation, including loss of cell polarity, appearance 
of spindle-shaped cells, and enlargement of the cell space 
(Fig. 2B and C). However, TE9 cells that were pretreated 
with 1 mM VPA did not show obvious morphologic changes 
(Fig. 2E and F).
The effect of VPA on changes in expression of epithelial and 
mesenchymal markers induced by TGF-β1 or irradiation in 
TE9 cells. To investigate the inhibitory effect of VPA on EMT 
induced by TGF-β1 or irradiation in TE9 cells, we examined 
the expression pattern of the epithelial marker E-cadherin 
and the mesenchymal marker vimentin with or without 
VPA treatment under TGF-β1 or irradiation stimulation by 
immunocytochemistry and western blot analysis (Fig. 3). TE9 
cells stimulated by TGF-β1 or irradiation showed a signifi-
cant decrease in E-cadherin expression and a concomitant 
increase in vimentin expression compared with control cells. 
Immunocytochemistry showed that E-cadherin expression at 
the membrane was completely lost after TGF-β1 or irradiation 
stimulation. In contrast, cells that were pretreated with 1 mM 
VPA showed less inhibition of E-cadherin expression than 
untreated cells when stimulated by TGF-β1 or irradiation. 
Vimentin expression was strongly increased and uniformly 
distributed under TGF-β1 or irradiation stimulation. 
Upregulation of vimentin expression by TGF-β1 or irradiation 
stimulation was clearly inhibited by VPA.
Effect of VPA on β-catenin translocation promoted by TGF-β1 
or irradiation in TE9 cells. One characteristic of EMT is break-
down of the cytoplasmic cell adhesion complex. Breakdown of 
Figure 1. Effect of VPA on proliferation and viability of TE9 cells. (A) MTT 
assay, (B) trypan blue exclusion assay. Data are represented as percentage of 
control (mean ± SEM) of three independent experiments (*P<0.05). MTT, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SEM, stan-
dard error of the mean.
Figure 2. Effect of VPA on morphologic changes of TE9 cells induced by TGF-β1 or irradiation. TE9 cells were incubated with 1 mM VPA for 3 h followed by 
treatment with TGF-β1 or irradiation. (A) Untreated control TE9 cells showed cobblestone-like morphology. (B and C) TGF-β1 (10 ng/ml) or irradiation (2 Gy) 
induced morphologic transformation to a spindle shape in TE9 cells. (D) VPA (1 mM) had no effect on TE9 morphology compared with control. (E and F) VPA 
(1 mM) inhibited spindle shape transformation induced by TGF-β1 or irradiation. Scale bar, 10 µm.
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this complex causes a change in the localization of β-catenin 
from its usual membrane-bound location. Immunofluorescence 
studies showed that β-catenin translocated to the nucleus or 
cytoplasm from its usual membrane-bound location 24-48 h 
after treatment with TGF-β1 or irradiation. Pretreatment with 
1 mM VPA inhibited these changes in the localization of 
β-catenin after TGF-β1 or irradiation stimulation (Fig. 4A). 
In contrast, the total amount of β-catenin protein assessed 
by western blot analysis was not altered by stimulation with 
TGF-β1 or irradiation or by pretreatment with VPA (Fig. 4B).
Effect of VPA on invasion and migration promoted by TGF-β1 
or irradiation stimulation in TE9 cells. To further understand 
the action of VPA on EMT, we investigated the effect of VPA 
on the enhancement of the invasive and migratory activity of 
TE9 cells by TGF-β1 or irradiation. Cells treated with TGF-β1 
or irradiation showed 1.55-fold (P=0.041) and 1.69-fold 
(P=0.038) enhanced invasion ability respectively compared 
with the control. Pretreatment with 1 mM VPA decreased 
the enhancement of TE9 cell invasiveness by TGF-β1 or irra-
diation (0.65-fold, P<0.01 and 0.63-fold enhancement, P<0.05, 
respectively) (Fig. 5A and B).
In the migration assay, TGF-β1- or irradiation-treated 
TE9 cells migrated almost completely across the leading 
edge after 48 h. TGF-β1 or irradiation significantly increased 
TE9 cell migration ability (1.49-fold, P<0.001 and 1.31-fold, 
P=0.03, respectively). Treatment with 1 mM VPA significantly 
suppressed the enhancement of TE9 cell migration ability 
by TGF-β1 or irradiation stimulation (0.82-fold, P<0.01 and 
0.86-fold, P<0.05, respectively) (Fig. 5 C and D).
Effect of VPA on the expression of EMT-related proteins 
and MMPs in TE9 cells. Interaction of TGF-β1 and TGF-β 
receptor type I (TβR-I) leads to phosphorylation of Smad2 
Figure 3. Effect of VPA on changes in the expression of epithelial and mes-
enchymal markers induced by TGF-β1 or irradiation in TE9 cells. Expression 
pattern of epithelial marker E-cadherin and mesenchymal marker vimentin 
with or without VPA (1 mM) under TGF-β1 (10 ng/ml) or irradiation (2 Gy) 
stimulation was examined by fluorescent immunocytochemistry (A) and 
western blot analysis (B). TE9 cells were stimulated by TGF-β1 (10 ng/ml) 
or irradiation (2 Gy) with or without VPA (1 mM). Nuclei were stained by 
Hoechst 33258. Scale bar, 25 µm.
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and Smad3, the key mediators of TGF-β1 signaling. Therefore, 
we examined TGF-β1 expression and Smad2 and Smad3 
phosphorylation after stimulation by TGF-β1 or irradiation. 
Stimulation by TGF-β1 or irradiation resulted in increased 
TGF-β1 expression. Consistent with this finding, stimulation 
by TGF-β1 or irradiation also induced Smad2 and Smad3 
phosphorylation. Administration of VPA (1 mM) abolished 
both responses. Total Smad2 and Smad3 were abundant 
in control cells, and expression levels were not affected by 
TGF-β1, irradiation, or VPA treatment (Fig. 6). Exposure of 
serum-starved TE9 cells to TGF-β1 or irradiation resulted in 
increased phosphorylation of Smad2 and Smad3. Incubation 
with 1 mM VPA suppressed phosphorylation of Smad2 and 
Smad3 after TGF-β1 or irradiation stimulation, whereas expres-
sion of total Smad2 and Smad3 was not affected (Fig. 6A), 
confirming that VPA can block TGF-β1 signaling. We further 
delineated the link between TGF-β1- or irradiation-induced 
HIF-1α expression and EMT progression by showing that VPA 
(1 mM) suppressed HIF-1α expression. In addition, TGF-β1 
or irradiation strongly induced expression of the gelatinases 
MMP-2, MMP-7, and MMP-9 whereas VPA strongly inhibited 
the induction of these enzymes (Fig. 6B).
Effect of VPA on induction of transcription factor expression 
by TGF-β1 or irradiation stimulation in TE9 cells. Several 
key inducers of EMT are transcription factors such as Twist, 
Snail, and Slug that repress E-cadherin expression. Western 
blot analysis showed that TGF-β1 or irradiation stimulation 
induced upregulation of Twist, Snail, and Slug expression 
(Fig. 7). Pretreatment with VPA resulted in inhibition of Twist, 
Snail, and Slug expression.
Effect of VPA on the induction of stem cell markers by TGF-β1 
or irradiation stimulation in TE9 cell. By western blotting, 
Figure 4. Effect of VPA on β-catenin translocation promoted by TGF-β1 
or irradiation in TE9 cells. Localization and amount of β-catenin with or 
without VPA (1 mM) under TGF-β1 (10 ng/ml) or irradiation stimulation 
was analyzed by fluorescent immunocytochemistry (A) and western blot 
analysis (B). TGF-β1 (10 ng/ml) or irradiation (2 Gy) treated cells showed 
changes in localization of β-catenin from their usual cell membrane-
associated site to nuclear or cytoplasmic localization. Pretreatment of 
cells with 1 mM of VPA prevented the observed changes in localization 
of β-catenin. The total protein level of β-catenin was not altered. Scale 
bar, 25 µm.
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the level of total CD44 protein was increased by TGF-β1 
treatment or irradiation and was decreased by VPA (Fig. 8A). 
Fluorescence activated cell sorting (FACS) analysis also 
showed an increase in CD44 levels in TGF-β1 or irradiation-
Figure 5. Effect of VPA on invasion and migration promoted by TGF-β1 or irradiation stimulation in TE9 cells. Effect of VPA (1 mM) on invasion and migra-
tion promoted by TGF-β1 (10 ng/ml) or irradiation (2 Gy) stimulation in TE9 cells was analyzed by invasion assay (A and B) and migration assay (C and D). 
(A) Representative photomicrograph of invaded TE9 cells. (B) Invaded cells in each group was counted and compared. (C) Representative photomicrograph 
of scratch migration asssay. (D) Migrated cells in each group was counted and compared. TGF-β1 (10 ng/ml) or irradiation (2 Gy) significantly stimulated the 
invasion and migration ability of TE9 cells. VPA (1 mM) significantly inhibited the invasion and migration ability induced by TGF-β1 (10 ng/ml) or irradiation 
(2 Gy) stimulation. *P <0.05, **P <0.001. RI, radiation. Scale bar (A and B), 10 µm; (C and D), 100 µm.
Figure 6. Effect of VPA on the expression of EMT-related protein and MMPs in TE9 cells. Effect of VPA (1 mM) on the expression of EMT-related protein 
(TGF-β1, smad2, smad3, p-smad2, p-smad3 and HIF-1α) (A) and MMPs (B) was analyzed by western blot analysis.
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treated TE9 cells that was inhibited by VPA (Fig. 8B). These 
results indicate that TGF-β1 or irradiation exposure can alter 
cellular expression of markers associated with cancer stem-
like cell properties and that VPA inhibits transformation to a 
cancer stem-like phenotype.
Discussion
In this study, we demonstrated that irradiation induced 
morphologic and molecular alternations consistent with 
acquisition of a mesenchymal-like phenotype in ESCC cells. 
As a result of induction of EMT, ESCC cells attained invasive 
and migratory potential. In addition, the HDAC inhibitor VPA 
inhibited growth, invasion, migration, and the transformation 
to cancer stem-like phenotype associated with TGF-β1 or 
irradiation stimulation of ESCC cells.
Radiotherapy plays an important clinical role as the major 
non-surgical treatment for esophageal cancer. However, 
previous studies have reported that irradiation may enhance 
the metastatic potential of residual cancer (6,18). Local failure 
and distant metastasis are the primary causes of radiotherapy 
Figure 7. Interactive effect of VPA on transcription factors induced by 
TGF-β1 or irradiation stimulation. Effect of VPA (1 mM) on the expression 
of transcription factors (twist, snail and slug) promoted by TGF-β1 (10 ng/
ml) or irradiation (2 Gy) stimulation in TE9 cells was analyzed by western 
blot analysis.
Figure 8. Effect of VPA on the expression of CD44 in TE9 cells. The effect of VPA (1 mM) on the expression of CD44 was analyzed by western blot analysis 
(A) and flow cytometry (B).
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failure. Therefore, tumor recurrence and metastasis might be 
associated with tumor biological behavior, as well as with 
EMT induced by irradiation. Recently, examination of a radio-
resistant ESCC cell line obtained after fractionated radiation 
treatment showed that fractionated irradiation promoted EMT 
(19). In this study, we examined whether single-dose irradia-
tion can induce EMT in TE9 ESCC cells. We showed that 2 Gy 
of irradiation induced spindle cell-like morphologic changes, 
decreased expression of membranous E-cadherin, upregulated 
vimentin expression, and changed the localization of β-catenin 
from its usual membrane-bound location to the cytoplasm. 
Furthermore, we showed upregulation of transcription factors 
Slug, Snail, and Twist, which regulate EMT (32). These find-
ings indicate that single-dose irradiation also induces EMT in 
ESCC cells. We also found that 2 Gy of irradiation induced 
EMT in other ESCC cell lines including TE10 (well differenti-
ated type), TE11 (moderately differentiated type), and KES 
(well differentiated type) (data not shown).
One of the major pathways of EMT is the TGF-β1/Smad 
pathway. Components of the TGF-β1/Smad signaling pathway 
are well known as an important signal transducers for cell 
proliferation, differentiation, and survival, and also serve 
as key factors in the regulation of cancer cell invasion and 
metastasis. In mice bearing tumor cells, irradiation causes 
increased circulating levels of TGF-β1 as well as increased 
circulating tumor cells and lung metastasis (17). We similarly 
found that irradiation induced intracellular accumulation of 
TGF-β1 and increased phosphorylation of Smad2 and Smad3, 
key mediators of TGF-β1 signaling. Although the molecular 
basis of a functional interaction between hypoxia, HIF-1α, 
and TGF-β1 signaling is not well understood at this point, the 
simplest explanation is that TGF-β1 levels increase in response 
to hypoxia (33). In this study, irradiation increased HIF-1α 
expression at the protein level, and irradiation-induced HIF-1α 
further upregulated the expression of MMPs. HIF-1α is known 
as the key regulator of the cellular response to hypoxia. Induced 
expression of HIF-1α and its target genes plays a critical role 
in cell growth, metastasis, and resistance to radiotherapy (33). 
It is noteworthy that irradiation enhanced the invasion and 
migration ability of TE9 cells, possibly through the upregula-
tion of MMPs. Recent studies indicate that MMPs can activate 
EMT (34). MMPs cleave cell-ECM adhesion proteins and cell-
cell junction proteins, releasing individual epithelial cells from 
epithelial sheets and initiating outside-in signaling pathways 
that lead to widespread changes in gene transcription patterns 
(34). Upregulation of HIFs in cancer cells may also occur in 
the hypoxic intra-tumoral regions formed within primary 
and secondary neoplasms. Cancer cells stimulated by HIF-1α 
show enhanced production of TGF-β1, thus the TGF-β1/Smad 
pathway is activated and consequent production of transcrip-
tion factors is increased, leading to EMT. The expression 
of TGF-β1 is further enhanced, stimulating expression of 
cancer stem cell markers such as CD44 and CD133, which 
are considered to play a role in the acquisition of cancer stem 
cell-like properties by cancer cells. We showed that irradiation 
induced CD44 expression in TE9 cells. It might therefore be 
speculated that TE9 cells obtained stem cell-like character-
istics after irradiation. It is likely that cancer stem cells are 
responsible for initiation, progression, recurrence, metastasis, 
and chemoradiotherapy resistance of cancer (35). Therefore, 
fractionated irradiation might induce radioresistance through 
the acquisition of cancer stem cell-like characteristics. In this 
study, we administered irradiation at a single dose of 2 Gy, a 
dose that reduced TE9 cell survival to 30% in our previous 
study (27). Although 2 Gy of radiation killed the majority 
of the ESCC cells, the cells that survived after irradiation 
showed EMT and cancer stem cell-like characteristics with 
increased invasive, migration, and radioresistant phenotypes. 
These findings are consistent with recent reports that tumor 
cells can gain cancer stem cell properties as a result of EMT 
(36), leading to a higher probability of metastasis and radia-
tion/drug resistance.
HDAC inhibitors are now considered to be promising anti-
cancer agents and some of these compounds, including VPA, 
are near clinical stage or already on the market. Lei et al (37) 
showed that HDAC1 is required for TGF-β1-induced EMT 
and cell migration in hepatocytes. Recently, several reports 
showed that HDAC inhibitor suppress EMT in various cells, 
including cancer cells (31,38,39). HDAC inhibitors suppress 
metastatic potential and reverse chemoresistance in cancer 
cells through suppression of EMT (30,31). Although the 
majority of reports support a suppressive effect of HDAC 
inhibitors on EMT, two reports show that the class I and II 
HDAC inhibitor VPA promotes EMT of colorectal cancer 
cells (40,41). Therefore, we investigated the inhibitory effect 
of VPA on irradiation-induced EMT in ESCC cells. We 
found that VPA clearly inhibited EMT induced by TGF-β1 
or irradiation in these cells. Thus, VPA inhibits EMT and 
acquisition of cancer stem cell-like properties in ESCC cells. 
VPA might have a mutually exclusive effect on EMT between 
squamous cell carcinoma and adenocarcinoma; further 
studies are needed to confirm this apparent conflicting action 
of VPA on EMT.
We have previously demonstrated the synergistic effect of 
VPA on radiation therapy against ESCC (27). VPA enhances 
the radiosensitivity of ESCC cells through chromatin decon-
densation with histone hyperacetylation and increases the level 
of radiation-induced DNA DSBs. VPA inhibits DNA DSB 
repair by homologous recombination through the suppression 
of Rad51 and by non-homologous end joining through the 
acetylation of Ku70 (27,28). As shown in this study, VPA can 
also suppress radiation-induced EMT, leading to inhibition 
of invasion and metastasis, and reducing resistance to further 
chemoradiotherapy.
We performed the same experiments using well-differen-
tiated, moderately differentiated type, poorly differentiated 
types of ESCC cell and found that the poorly differentiated 
type showed the most remarkable changes in EMT (data not 
shown). Clinically, this suggests that cases of poorly differ-
entiated squamous cell carcinoma are good candidates for 
combined VPA treatment with radiation therapy.
EMT is classified into three types depending on its biologic 
or pathologic role. Type 2 EMT is associated with inflamma-
tion and fibrosis, and is becoming increasingly recognized in 
adult pathologic conditions (42). Some reports show the effec-
tiveness of chemoradiotherapy as neoadjuvant treatment for 
esophageal cancer. Surgery for esophageal cancer after radio-
therapy is sometimes complicated by fibrosis. Concomitant 
usage of VPA during neoadjuvant radiotherapy might be 
useful to avoid fibrosis around the tumor bed.
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In conclusion, irradiation enhances the invasiveness of 
ESCC, partially through morphologic and molecular changes 
such as EMT and the induction of stem cells. Simultaneous 
use of the HDAC inhibitor VPA and radiotherapy might be 
useful not only to eradicate local disease, but also to control 
the systemic dissemination or metastasis associated with 
radiotherapy. Our data suggest that VPA might be an ideal 
therapeutic agent when combined with radiation for the treat-
ment of ESCC.
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